Marinus Pharmaceuticals (NASDAQ:MRNS) : Zacks Investment Research ranks Marinus Pharmaceuticals (NASDAQ:MRNS) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2.5, which indicates as a Buy.
Marinus Pharmaceuticals (NASDAQ:MRNS) : The highest level Marinus Pharmaceuticals (NASDAQ:MRNS) is projected to reach is $17 for the short term and the lowest estimate is at $2. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $7.17 and the possibility the share price can swing is $8.52.
For the current week, the company shares have a recommendation consensus of Buy. Also, RBC Capital downgrades their rating on the shares of Marinus Pharmaceuticals (NASDAQ:MRNS). The current rating of the shares is Sector Perform. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on June 14, 2016.
Marinus Pharmaceuticals (NASDAQ:MRNS): stock turned positive on Tuesday. Though the stock opened at $1.33, the bulls momentum made the stock top out at $1.4 level for the day. The stock recorded a low of $1.25 and closed the trading day at $1.3, in the green by 4.84%. The total traded volume for the day was 1,327,174. The stock had closed at $1.24 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Marinus Pharmaceuticals Inc, Cashman Christopher Michael had purchased shares worth of $19,977 in a transaction dated on November 6, 2015. A total of 3,561 shares were purchased at a price of $5.61 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Companys indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Companys oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.